According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...

Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Researchers have found in a new study that Use of GLP-1 receptor agonists before pregnancy was associated with reduced risks ...

Two new class action complaints, both captioned Robins v. Lemme Inc., were filed in in California Superior Court and the Southern District of New ...

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX ...